{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:25:14Z","timestamp":1787153114354,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"DOI":"10.7759\/cureus.114792","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:32:39Z","timestamp":1787149959000},"source":"Crossref","is-referenced-by-count":0,"title":["Polycystic Kidney Disease-Related Mortality in the US (1999-2024): A Nationwide Joinpoint Analysis of Trends, Disparities, and Comorbidity Structure"],"prefix":"10.7759","author":[{"given":"Hamza B","family":"Amir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Uzair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenab M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haashir A","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astad Y","family":"Sidhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres VE","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007, 369:1287-1301. 10.1016\/s0140-6736(07)60601-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03484-3","article-title":"Mortality risk in patients with autosomal dominant polycystic kidney disease","volume":"25","author":"Mladsi D","year":"2024","unstructured":"Mladsi D, Zhou X, Mader G, et al.. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024, 25:56. 10.1186\/s12882-024-03484-3","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000494923","article-title":"Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015","volume":"5","author":"Willey C","year":"2019","unstructured":"Willey C, Kamat S, Stellhorn R, Blais J. Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015. Kidney Dis (Basel). 2019, 5:107-17. 10.1159\/000494923","journal-title":"Kidney Dis (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190430","article-title":"The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition","volume":"13","author":"Solazzo A","year":"2018","unstructured":"Solazzo A, Testa F, Giovanella S, et al.. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018, 13:e0190430. 10.1371\/journal.pone.0190430","journal-title":"PLoS ONE"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27720","article-title":"Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality","volume":"38","author":"Perrone RD","year":"2001","unstructured":"Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001, 38:777-84. 10.1053\/ajkd.2001.27720","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.07.017","article-title":"Cardiovascular manifestations and management in ADPKD","volume":"8","author":"Sagar PS","year":"2023","unstructured":"Sagar PS, Rangan GK. Cardiovascular manifestations and management in ADPKD. Kidney Int Rep. 2023, 8:1924-40. 10.1016\/j.ekir.2023.07.017","journal-title":"Kidney Int Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr467","article-title":"Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease","volume":"27","author":"Orskov B","year":"2012","unstructured":"Orskov B, S\u00f8rensen VR, Feldt-Rasmussen B, Strandgaard S. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2012, 27:1607-13. 10.1093\/ndt\/gfr467","journal-title":"Nephrol Dial Transplant"},{"key":"ref8","unstructured":"FDA approves tolvaptan for ADPKD. (2018). https.\/\/www.kidneynews.org\/view\/journals\/kidney-news\/10\/6\/article-p17_12.xml."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres VE","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al.. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017, 377:1930-42. 10.1056\/NEJMoa1710030","journal-title":"N Engl J Med"},{"key":"ref10","unstructured":"Kidney allocation system. Accessed. June 15, 2026: https:\/\/optn.transplant.hrsa.gov\/professionals\/by-organ\/kidney-pancreas\/kidney-allocation-system\/."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04720-x","article-title":"Mortality trends from acute MI with underlying CKD in the US from 1999 to 2020: a cross-sectional analysis of the CDC WONDER database","volume":"58","author":"Nabi R","year":"2026","unstructured":"Nabi R, Mansoor MH, Shahbaz MH, et al.. Mortality trends from acute MI with underlying CKD in the US from 1999 to 2020: a cross-sectional analysis of the CDC WONDER database. Int Urol Nephrol. 2026, 58:653-60. 10.1007\/s11255-025-04720-x","journal-title":"Int Urol Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047314","article-title":"Pediatric demographics and regional trends from congenital anomalies of the kidney and urinary tract: a U.S. population-based study from 1999 to 2020","volume":"105","author":"Ibrahim M","year":"2026","unstructured":"Ibrahim M, Ahmad MH, Zahid H, et al.. Pediatric demographics and regional trends from congenital anomalies of the kidney and urinary tract: a U.S. population-based study from 1999 to 2020. Medicine (Baltimore). 2026, 105:e47314. 10.1097\/MD.0000000000047314","journal-title":"Medicine (Baltimore)"},{"key":"ref13","unstructured":"Multiple cause of death, 1999-2020 and 2018-2024. Accessed. June 15, 2026: https:\/\/wonder.cdc.gov\/mcd.html."},{"key":"ref14","article-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","year":"2016","unstructured":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). World Health Organization, 2016."},{"key":"ref15","article-title":"Age standardization of death rates: implementation of the year 2000 standard","volume":"47","author":"Anderson RN","year":"1998","unstructured":"Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998, 47:1-16.","journal-title":"Natl Vital Stat Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim HJ","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000, 19:335-51. 10.1002\/(sici)1097-0258(20000215)19:3&lt;335::aid-sim336&gt;3.0.co;2-z","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol EI","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, et al.. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015, 12:e1001885. 10.1371\/journal.pmed.1001885","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03140319","article-title":"Trends in Disparities in Preemptive Kidney Transplantation in the United States","volume":"14","author":"King KL","year":"2019","unstructured":"King KL, Husain SA, Jin Z, Brennan C, Mohan S. Trends in Disparities in Preemptive Kidney Transplantation in the United States. Clin J Am Soc Nephrol. 2019, 14:1500-11. 10.2215\/CJN.03140319","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/2054358118778568","article-title":"End-stage kidney disease in patients with autosomal dominant polycystic kidney disease: a 12-year study based on the Canadian Organ Replacement Registry","volume":"5","author":"Budhram B","year":"2018","unstructured":"Budhram B, Akbari A, Brown P, et al.. End-stage kidney disease in patients with autosomal dominant polycystic kidney disease: a 12-year study based on the Canadian Organ Replacement Registry. Can J Kidney Health Dis. 2018, 5:2054358118778568. 10.1177\/2054358118778568","journal-title":"Can J Kidney Health Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00840122","article-title":"Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States","volume":"17","author":"McGill RL","year":"2022","unstructured":"McGill RL, Saunders MR, Hayward AL, Chapman AB. Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022, 17:976-85. 10.2215\/CJN.00840122","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100577","article-title":"Health disparities in kidney failure among patients with autosomal dominant polycystic kidney disease: a cross-sectional study","volume":"5","author":"Harrison TN","year":"2023","unstructured":"Harrison TN, Chen Q, Lee MY, et al.. Health disparities in kidney failure among patients with autosomal dominant polycystic kidney disease: a cross-sectional study. Kidney Med. 2023, 5:100577. 10.1016\/j.xkme.2022.100577","journal-title":"Kidney Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021010009","article-title":"Initial effects of COVID-19 on patients with ESKD","volume":"32","author":"Weinhandl ED","year":"2021","unstructured":"Weinhandl ED, Wetmore JB, Peng Y, Liu J, Gilbertson DT, Johansen KL. Initial effects of COVID-19 on patients with ESKD. J Am Soc Nephrol. 2021, 32:1444-53. 10.1681\/ASN.2021010009","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry","volume":"29 Suppl 4","author":"Spithoven EM","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, et al.. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014, 29 Suppl 4:iv15-25. 10.1093\/ndt\/gfu017","journal-title":"Nephrol Dial Transplant"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12963-017-0123-7","article-title":"Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014)","volume":"15","author":"Fernando MR","year":"2017","unstructured":"Fernando MR, Dent H, McDonald SP, Rangan GK. Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014). Popul Health Metr. 2017, 15:7. 10.1186\/s12963-017-0123-7","journal-title":"Popul Health Metr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-39","article-title":"Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease","volume":"15","author":"Yoo DJ","year":"2014","unstructured":"Yoo DJ, Agodoa L, Yuan CM, Abbott KC, Nee R. Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease. BMC Nephrol. 2014, 15:39. 10.1186\/1471-2369-15-39","journal-title":"BMC Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522991-polycystic-kidney-disease-related-mortality-in-the-us-1999-2024-a-nationwide-joinpoint-analysis-of-trends-disparities-and-comorbidity-structure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:32:42Z","timestamp":1787149962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522991-polycystic-kidney-disease-related-mortality-in-the-us-1999-2024-a-nationwide-joinpoint-analysis-of-trends-disparities-and-comorbidity-structure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.114792","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}